Safety profiles of atypical antipsychotics in the elderly
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
The advent of atypical antipsychotics has allowed for the treatment of psychosis with improved patient tolerability compared with conventional neuroleptics. Atypicality has been defined in terms of fewer extrapyramidal symptoms, as well as enhanced efficacy against the negative symptoms of schizophrenia. However, the atypical antipsychotics are not a panacea for psychosis; they are not without their own potential for adverse effects. In the geriatric population, the use of antipsychotics has been extended to include the treatment of behavioral sequelae associated with dementia and delirium, especially in the nursing home setting. Compared with their younger counterparts, special consideration must be given for elderly patients in light of physiologic differences associated with aging and an increased prevalence of comorbid medical conditions. These differences can potentially reduce tolerability of these medications. This review examines the evidence for particular adverse effects associated with aripiprazole, clozapine, olanzapine, quetiapine, risperidone, and ziprasidone in the older patient population.
- Tandon R, Jibson MD. Extrapyramidal side effects of antipsychotic treatment: scope of problem and impact on outcome. Ann Clin Psychiatry 2002, 14:123–129. CrossRef
- Older Americans 2000: key indicators of well-being. http://www.agingstats.gov/chartbook2000/default.htm. Accessed December 7, 2003.
- Kawas C, Gray S, Brookmeyer R, et al.: Age-specific incidence rates of Alheimer’s disease: the Baltimore Longitudinal Study of Aging. Neurology 2000, 54:2072–2077.
- Greenblatt DJ, Abernathy DR, Shader RI: Pharmacokinetic aspects of drug therapy in the elderly. Ther Drug Monit 1986, 8:249–255. CrossRef
- Shen WW: A history of antipsychotic drug development. Comprehens Psychiatry 1999, 40:407–414. CrossRef
- Herst L, Powell G: Is clozapine safe in the elderly? Aust N Z J Psychiatry 1997, 31:411–417.
- Sajatovic M, Jaskiw G, Konicki PE, et al.: Outcome of clozapine therapy for elderly patients with refractory primary psychosis. Int J Geriatr Psychiatry 1997, 12:553–558. CrossRef
- Street JS, Clark S, Gannon K, et al.: Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities. Arch Gen Psychiatry 2000, 57:968–976. CrossRef
- Fontaine CS, Hynan LS, Koch K, et al.: A double-blind comparison of olanzapine versus risperidone in acute treatment of dementia-related behavioral disturbances in extended care facilities. J Clin Psychiatry 2003, 64:726–730. CrossRef
- Hwang JP, Yang CH, Lee TW, Tsai SJ: The efficacy and safety of olanzapine for the treatment of geriatric psychosis. J Clin Psychopharmacol 2003, 23:113–118. CrossRef
- Barak Y, Shamir E, Zemishlani H, et al.: Olanzapine versus haloperidol in the treatment of elderly chronic schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:1199–1202. CrossRef
- Tariot PN, Salzman C, Yueng PP, et al.: Long-term use of quetiapine in elderly patients with psychotic disorders. Clin Therapeut 2000, 22:1068–1084. CrossRef
- Madhusoodanan S, Brenner R, Alcantra A: Clinical experience with quetiapine in elderly patients with psychotic disorders. J Geriatr Psychiatry Neurol 2000, 13:28–32. CrossRef
- Dogu, O, Sevim S, Kaleagasi HS: Seizures associated with quetiapine treatment. Ann Pharmacother 2003, 37:1224–1227. CrossRef
- Fernandez HH, Trieschmann ME, Burke MA, et al.: Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Move Disord 2003, 18:510–514. CrossRef
- Takahashi H, Yoshida K, Sugita T, et al.: Quetiapine treatment of psychotic symptoms and aggressive behavior in patients with dementia with Lewy bodies: a case series. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:549–553. CrossRef
- Katz IR, Jeste DV, Mintzer JE, et al.: Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized double-blind trial. J Clin Psychiatry 1999, 60:107–115. CrossRef
- Brodaty H, Ames D, Snowdon J: A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia. J Clin Psychiatry 2003, 64:134–143. CrossRef
- Physicians’ Desk Reference, edn 58. Montvale, NJ: Medical Economics Company; 2003.
- De Deyn PP, Rabheru K, Rasmussen MD, et al.: A randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia. Neurology 1999, 53:946–955.
- Zarate CA, Baldessarini RJ, Siegel AJ, et al.: Risperidone in the elderly: a pharmacoepidemiologic study. J Clin Psychiatry 1997, 58:311–317.
- Leibson CI, Tosteson AN, Gabriel JE, Melton LJ: Mortality, disability and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002, 50:1644–1650. CrossRef
- Safety profiles of atypical antipsychotics in the elderly
Current Psychosis and Therapeutics Reports
Volume 2, Issue 1 , pp 21-26
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links